Breast cancer (BCa) is the leading cause of cancer-related deaths among women. Numerous efforts are being directed toward identifying novel tissue and/or circulating molecular markers that may help clinicians in detecting early-stage BCa patients and in providing an accurate estimation of the prognosis and prediction of response to clinical treatments. In this setting, emerging evidence has indicated Cystatin C (Cyst C), as the most potent endogenous inhibitor of cysteine cathepsins, as a possible useful marker in the clinical management of BCa patients.
Leto, G., & Sepporta, M.V. (2020). The potential of cystatin C as a predictive biomarker in breast cancer.
Data di pubblicazione: | 2020 | |
Titolo: | The potential of cystatin C as a predictive biomarker in breast cancer | |
Autori: | ||
Citazione: | Leto, G., & Sepporta, M.V. (2020). The potential of cystatin C as a predictive biomarker in breast cancer. | |
Rivista: | ||
Digital Object Identifier (DOI): | http://dx.doi.org/10.1080/14737140.2020.1829481 | |
Abstract: | Breast cancer (BCa) is the leading cause of cancer-related deaths among women. Numerous efforts are being directed toward identifying novel tissue and/or circulating molecular markers that may help clinicians in detecting early-stage BCa patients and in providing an accurate estimation of the prognosis and prediction of response to clinical treatments. In this setting, emerging evidence has indicated Cystatin C (Cyst C), as the most potent endogenous inhibitor of cysteine cathepsins, as a possible useful marker in the clinical management of BCa patients. | |
Appare nelle tipologie: | 1.09 Review essay (rassegna critica) |
File in questo prodotto:
File | Descrizione | Tipologia | Licenza | |
---|---|---|---|---|
ERCT CystBCa 2020.pdf | Versione Editoriale | Administrator Richiedi una copia |